Targeting HDAC6 Reprograms TH 17 Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.
Hepatocellular carcinoma (HCC) often accompanies with resistance to immunotherapies despite the presence of tumor-infiltrating lymphocytes. Here we report that HDAC6 represses TH 17 cell pathogenicity and antitumor immune response dependent on its deacetylase activity. Adoptive transfer of HDAC6-deficient TH 17 cell impedes HCC growth dependent on elevated IL-17A via enhancing the production of antitumor cytokine and CD8+ T cell-mediated antitumor responses. Intriguingly, HDAC6-depleted T cells triggers PD-1-PD-L1 expression to achieve a strong synergistic effect to sensitize advanced HCC to immune checkpoint blocker, while blockade of IL-17A partially suppresses it. Mechanistically, HDAC6 limits TH 17 pathogenicity and antitumor effect through regulating FoxO1. HDAC6 binds and deacetylates cytosolic FoxO1 at K242, which is required for its nuclear translocation and stabilization to repress RoRγt, the transcription factor of TH 17 cell. This regulation of HDAC6 for murine and human TH 17 cell is highly conserved. CONCLUSION: These results demonstrate targeting cytosolic HDAC6-FoxO1 axis reprograms the pathogenicity and antitumor response of TH 17 cells in HCC, with a pathogenicity-driven responsiveness to facilitate immunotherapies.